恒瑞医药药品纳入拟突破性治疗品种公示名单

Core Insights - Heng Rui Medicine (600276.SH) announced that its subsidiaries, Suzhou Shengdiya Biopharmaceutical Co., Ltd. and Shanghai Shengdi Medicine Co., Ltd., have had their injection products, SHR-A1811 (Rocatinib) and Adebali monoclonal antibody injection, included in the National Medical Products Administration's (NMPA) list of proposed breakthrough therapies [1] Group 1 - The inclusion of SHR-A1811 in the proposed breakthrough therapy list marks its 9th time being recognized [1]